FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, particularly to methods for enhancing multiplication of natural killer (NK) cells (embodiments). In one embodiment, said method involves (a) co-cultivation in a culture medium of a population of NK cells with a population of feeder cells containing cells engineered to express 4-1BBL and membrane-bound interleukin-15 (mbIL15); (b) enriching the culture medium with interleukin-2 (IL2) and (c) enriching the culture medium with at least one soluble stimulant, which is a combination (i) soluble interleukin-12 and soluble interleukin-18 (IL18).
EFFECT: present invention provides intensified reproduction of natural killers and their cytotoxicity against target cells.
24 cl, 37 dwg, 1 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC COMPOUNDS AND METHODS | 2016 |
|
RU2770001C2 |
| MESENCHYMAL STEM CELLS ORIGINATING FROM PERINATAL TISSUE: METHOD FOR THEIR PRODUCTION AND USE | 2017 |
|
RU2780179C2 |
| COMPOSITIONS AND METHODS FOR STIMULATING NATURAL KILLER CELLS | 2020 |
|
RU2839664C2 |
| MODIFIED HEMATOPOIETIC STEM CELLS/PROGENITOR CELLS AND NON-T EFFECTOR CELLS, AND USE THEREOF | 2014 |
|
RU2733652C2 |
| METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
| CRYOPRESERVED CELLS ARE NATURAL KILLERS PRELOADED WITH ANTIBODY CONSTRUCTION | 2019 |
|
RU2819927C2 |
| COMPOSITION FOR ANTICANCER TREATMENT CONTAINING NK-CELLS AND FUSION PROTEIN WHICH CONTAINS IL-2 PROTEIN AND CD80 PROTEIN | 2020 |
|
RU2832136C1 |
| ANTI-CD38 ANTIBODIES AND FORMULATIONS | 2020 |
|
RU2826957C2 |
| NK CELL LINE EXPRESSING PSMA-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND SECRETING CD47/SIRPA INTERACTION BLOCKER | 2020 |
|
RU2757353C1 |
| POLYVALENT BINDING PROTEINS FOR ACTIVATION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC APPLICATION FOR TREATMENT OF MALIGNANT NEOPLASM | 2018 |
|
RU2809125C2 |
